

FROM LIFE SCIENCE START-UP TO PUBLICLY LISTED COMPANY

- Challenges on the journey

TIME AND PLACE

20 OCTOBER 2020 | 15.30 – 17.30 KROMANN REUMERT | SUNDKROGSGADE 5 | DK-2100 COPENHAGEN

PROGRAM

15.30-15.40	INTRODUCTION Oliver Machholdt, Partner, Kromann Reumert, and DALILA board member
15.40-16.10	 ENTREPRENEUR GAME Morten Albrechtsen, CEO, FluoGuide A/S When is an idea worth investing in and when is the game over Dynamics of life science start-ups Pros and cons of early listing on stock exchange – case study: FluoGuide A/S
16.10 – 16.40	 THE CHALLENGES Nanna Luneborg, Partner, Novo Ventures The VC perspective: Is it a good idea at all to take a biotech company public? When is the right time? Going public in Europe vs. United States
16.40 – 17.10	 THE JOURNEY TO IPO Anders Fink Vadsholt, CFO, Ophazyme Reflections on Ophazyme's journey from start-up to IPO The role of investors in a life science start-up and later in an IPO
17.10 – 17.25	Q&A
17.25 – 17.30	ROUND-UP AND THANK YOU FOR TODAY
PARKING	Free parking is available in Kromann Reumert's underground car parking. The ramp is to your left when you come off Sundkrogsgade. When the light is green, the gate is open and will stay open when you pass through.
CORONAVIRUS/ COVID-19	Kromann Reumert takes the safety, security and health of its employees and guests very seriously. We adhere to the coronavirus recommenda- tions issued by the government, also in connection with events, which are of course planned in compliance with the guidelines in order to cre- ate a safe environment for everyone. This means that you are not al- lowed to attend an event if you or members of your household display any symptoms of COVID-19. You can read more about the government's recommendations and auidelines on www.coronasmitte.dk.

